Other Clinical Trial - Immunmodulation in Patients With HHT

Status Completed

Clinical Trial Summary

Hereditary haemorrhagic telangiectasia (HHT), also known as Rendu-Osler-Weber syndrome, is an inherited multisystemic disorder. Literature suggests that HHT is often associated with higher frequency of infectious diseases.

The purpose of this study is to evaluate a variety of immunologic parameters in the blood serum of HHT patients in comparison to probands.

Clinical Trial Description

Hereditary haemorrhagic telangiectasia (HHT), also known as Rendu-Osler-Weber syndrome, is an inherited multisystemic disorder with recurrent epistaxis, mucocutaneous telangiectasia and visceral arteriovenous malformations. Literature and the investigators' observation suggest that HHT is often associated with higher frequency of infectious diseases. This might be a hint for a immunocompromised situation.

The purpose of this study is to evaluate a variety of immunologic parameters in the blood serum of HHT patients in comparison to probands. ;

Study Design

Related Conditions & MeSH terms

Hereditary Haemorrhagic Telangiectasia (HHT)
Telangiectasia, Hereditary Hemorrhagic
Telangiectasis

Clinical Trial Details

NCT number	NCT02983253
Study type	Observational
Source	University Hospital, Essen
Contact
Status	Completed
Phase
Start date	June 2016
Completion date	October 2019

View Details

See also
	Status	Clinical Trial	Phase
	Completed	`NCT02690246` - Symptoms and Treatment Results in Hereditary Hemorrhagic Telangiectasia
	Completed	`NCT01692015` - Diet and Hereditary Haemorrhagic Telangiectasia	N/A